Transcriptional profiling revealed upregulation of the mevalonate/cholesterol biosynthesis pathway in TP53 deficient AML cells, promoting membrane stability, redox homeostasis, and immune evasion [209]. This evidence concerns the gene TP53 and acute myeloid leukemia.